Guo’s findings suggested that clinical outcomes might be influenced by SNPs (single nucleotide polymorphisms) in MCT1 and MCT2 genes, which could be used to predict the response to adjuvant chemotherapy in patients with NSCLC receiving surgical treatment in future study [36]. Here, SLC16A1 is linked to non-small cell lung carcinoma.